Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OT9HRPL6)

• DOT Name: Myeloid-derived growth factor (MYDGF)
• Synonyms: MYDGF
• Gene Name: MYDGF
• Related Disease:
  Arteriosclerosis
  Atherosclerosis
  Nervous system inflammation
  Psoriasis
  Systemic lupus erythematosus
  Acute myocardial infarction
  Adult lymphoma
  Allergic rhinitis
  Arthritis
  Asthma
  Atopic dermatitis
  Autoimmune disease
  Breast cancer
  Breast carcinoma
  Carcinoma of esophagus
  Chronic obstructive pulmonary disease
  Crohn disease
  Dermatitis
  Diabetic retinopathy
  Epithelial ovarian cancer
  Hepatocellular carcinoma
  Inflammatory bowel disease
  Keloid
  Lupus
  Lymphoma
  Melanoma
  Multiple sclerosis
  Nasal polyp
  Non-small-cell lung cancer
  Obesity
  Pediatric lymphoma
  Pneumonia
  Pulmonary tuberculosis
  Rheumatoid arthritis
  Sjogren syndrome
  Tuberculosis
  Ulcerative colitis
  Colitis
  HIV infectious disease
  Lung cancer
  Lung carcinoma
  Pneumonitis
  Allergic asthma
  Myocardial infarction
  Pancreatic cancer
  Prostate cancer
  Prostate carcinoma
• UniProt ID: MYDGF_HUMAN
• PDB ID: 6O6W; 6SVK; 6SVL
• Pfam ID: PF10572
• Sequence:
  MAAPSGGWNGVGASLWAALLLGAVALRPAEAVSEPTTVAFDVRPGGVVHSFSHNVGPGDK
  YTCMFTYASQGGTNEQWQMSLGTSEDHQHFTCTIWRPQGKSYLYFTQFKAEVRGAEIEYA
  MAYSKAAFERESDVPLKTEEFEVTKTAVAHRPGAFKAELSKLVIVAKASRTEL
• Function: Bone marrow-derived monocyte and paracrine-acting protein that promotes cardiac myocyte survival and adaptive angiogenesis for cardiac protection and/or repair after myocardial infarction (MI). Stimulates endothelial cell proliferation through a MAPK1/3-, STAT3- and CCND1-mediated signaling pathway. Inhibits cardiac myocyte apoptosis in a PI3K/AKT-dependent signaling pathway. Involved in endothelial cell proliferation and angiogenesis.
• Tissue Specificity: Expressed in eosinophils (at protein level) . Expressed in bone marrow cells . Expressed in synovial tissue. Found in synovial fluid of patients with arthropaties .
• Reactome Pathway: XBP1(S) activates chaperone genes (R-HSA-381038)

Molecular Interaction Atlas (MIA) of This DOT

47 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Arteriosclerosis	DISK5QGC	Definitive	Biomarker	[1]
Atherosclerosis	DISMN9J3	Definitive	Biomarker	[1]
Nervous system inflammation	DISB3X5A	Definitive	Biomarker	[2]
Psoriasis	DIS59VMN	Definitive	Biomarker	[3]
Systemic lupus erythematosus	DISI1SZ7	Definitive	Altered Expression	[4]
Acute myocardial infarction	DISE3HTG	Strong	Biomarker	[5]
Adult lymphoma	DISK8IZR	Strong	Biomarker	[6]
Allergic rhinitis	DIS3U9HN	Strong	Biomarker	[7]
Arthritis	DIST1YEL	Strong	Biomarker	[8]
Asthma	DISW9QNS	Strong	Biomarker	[9]
Atopic dermatitis	DISTCP41	Strong	Biomarker	[10]
Autoimmune disease	DISORMTM	Strong	Biomarker	[11]
Breast cancer	DIS7DPX1	Strong	Biomarker	[12]
Breast carcinoma	DIS2UE88	Strong	Biomarker	[12]
Carcinoma of esophagus	DISS6G4D	Strong	Genetic Variation	[13]
Chronic obstructive pulmonary disease	DISQCIRF	Strong	Altered Expression	[14]
Crohn disease	DIS2C5Q8	Strong	Altered Expression	[15]
Dermatitis	DISY5SZC	Strong	Biomarker	[16]
Diabetic retinopathy	DISHGUJM	Strong	Biomarker	[17]
Epithelial ovarian cancer	DIS56MH2	Strong	Genetic Variation	[13]
Hepatocellular carcinoma	DIS0J828	Strong	Biomarker	[18]
Inflammatory bowel disease	DISGN23E	Strong	Biomarker	[19]
Keloid	DISV09JY	Strong	Biomarker	[20]
Lupus	DISOKJWA	Strong	Biomarker	[21]
Lymphoma	DISN6V4S	Strong	Biomarker	[6]
Melanoma	DIS1RRCY	Strong	Biomarker	[22]
Multiple sclerosis	DISB2WZI	Strong	Biomarker	[23]
Nasal polyp	DISLP3XE	Strong	Biomarker	[24]
Non-small-cell lung cancer	DIS5Y6R9	Strong	Biomarker	[25]
Obesity	DIS47Y1K	Strong	Altered Expression	[26]
Pediatric lymphoma	DIS51BK2	Strong	Biomarker	[6]
Pneumonia	DIS8EF3M	Strong	Biomarker	[27]
Pulmonary tuberculosis	DIS6FLUM	Strong	Genetic Variation	[28]
Rheumatoid arthritis	DISTSB4J	Strong	Biomarker	[23]
Sjogren syndrome	DISUBX7H	Strong	Genetic Variation	[29]
Tuberculosis	DIS2YIMD	Strong	Biomarker	[30]
Ulcerative colitis	DIS8K27O	Strong	Genetic Variation	[31]
Colitis	DISAF7DD	moderate	Altered Expression	[15]
HIV infectious disease	DISO97HC	moderate	Genetic Variation	[32]
Lung cancer	DISCM4YA	moderate	Biomarker	[25]
Lung carcinoma	DISTR26C	moderate	Biomarker	[25]
Pneumonitis	DIS88E0K	Disputed	Biomarker	[27]
Allergic asthma	DISHF0H3	Limited	Biomarker	[33]
Myocardial infarction	DIS655KI	Limited	Biomarker	[34]
Pancreatic cancer	DISJC981	Limited	Biomarker	[35]
Prostate cancer	DISF190Y	Limited	Biomarker	[36]
Prostate carcinoma	DISMJPLE	Limited	Biomarker	[36]

This DOT Affected the Drug Response of 1 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Acetaminophen	DMUIE76	Approved	Myeloid-derived growth factor (MYDGF) affects the response to substance of Acetaminophen.	[49]

12 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the expression of Myeloid-derived growth factor (MYDGF).	[37]
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Myeloid-derived growth factor (MYDGF).	[38]
Tretinoin	DM49DUI	Approved	Tretinoin increases the expression of Myeloid-derived growth factor (MYDGF).	[39]
Doxorubicin	DMVP5YE	Approved	Doxorubicin increases the expression of Myeloid-derived growth factor (MYDGF).	[40]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate decreases the expression of Myeloid-derived growth factor (MYDGF).	[41]
Cisplatin	DMRHGI9	Approved	Cisplatin decreases the expression of Myeloid-derived growth factor (MYDGF).	[42]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Myeloid-derived growth factor (MYDGF).	[43]
Cytarabine	DMZD5QR	Approved	Cytarabine decreases the expression of Myeloid-derived growth factor (MYDGF).	[44]
Dihydrotestosterone	DM3S8XC	Phase 4	Dihydrotestosterone increases the expression of Myeloid-derived growth factor (MYDGF).	[45]
THAPSIGARGIN	DMDMQIE	Preclinical	THAPSIGARGIN increases the expression of Myeloid-derived growth factor (MYDGF).	[46]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A decreases the expression of Myeloid-derived growth factor (MYDGF).	[47]
Milchsaure	DM462BT	Investigative	Milchsaure decreases the expression of Myeloid-derived growth factor (MYDGF).	[48]

References

• [1] ILC2 transfers to apolipoprotein E deficient mice reduce the lipid content of atherosclerotic lesions.BMC Immunol. 2019 Dec 10;20(1):47. doi: 10.1186/s12865-019-0330-z.
• [2] Cutting Edge: IL-27 Attenuates Autoimmune Neuroinflammation via Regulatory T Cell/Lag3-Dependent but IL-10-Independent Mechanisms In Vivo.J Immunol. 2019 Mar 15;202(6):1680-1685. doi: 10.4049/jimmunol.1800898. Epub 2019 Jan 30.
• [3] The IL-23p19/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man.Inflamm Res. 2019 Jun;68(6):423-426. doi: 10.1007/s00011-019-01235-x. Epub 2019 Apr 13.
• [4] Elevated interleukin-25 and its association to Th2 cytokines in systemic lupus erythematosus with lupus nephritis.PLoS One. 2019 Nov 7;14(11):e0224707. doi: 10.1371/journal.pone.0224707. eCollection 2019.
• [5] Elevated IL-27 in patients with acute coronary syndrome is associated with adverse ventricular remodeling and increased risk of recurrent myocardial infarction and cardiovascular death.Cytokine. 2019 Oct;122:154208. doi: 10.1016/j.cyto.2017.11.002. Epub 2018 Feb 7.
• [6] Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjgren's Syndrome.Arthritis Rheumatol. 2018 Aug;70(8):1265-1275. doi: 10.1002/art.40500. Epub 2018 Jun 27.
• [7] Interleukin-27 inhibits helper T cell type-2 response in allergic rhinitis.Auris Nasus Larynx. 2020 Feb;47(1):84-89. doi: 10.1016/j.anl.2019.05.005. Epub 2019 May 30.
• [8] IL-27: a double agent in the IL-6 family.Clin Exp Immunol. 2018 Jul;193(1):37-46. doi: 10.1111/cei.13116. Epub 2018 Mar 9.
• [9] Anti-alarmin approaches entering clinical trials.Curr Opin Pulm Med. 2020 Jan;26(1):69-76. doi: 10.1097/MCP.0000000000000615.
• [10] Eupatilin, an activator of PPAR, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice.Biochem Biophys Res Commun. 2018 Feb 5;496(2):508-514. doi: 10.1016/j.bbrc.2018.01.098. Epub 2018 Jan 17.
• [11] A folding switch regulates interleukin 27 biogenesis and secretion of its -subunit as a cytokine.Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1585-1590. doi: 10.1073/pnas.1816698116. Epub 2019 Jan 16.
• [12] IL-25 blockade inhibits metastasis in breast cancer.Protein Cell. 2017 Mar;8(3):191-201. doi: 10.1007/s13238-016-0345-7. Epub 2016 Dec 1.
• [13] Common Polymorphisms in IL-27 Genes May Contribute to Risk of Various Human Diseases in Asian Populations: A Meta-Analysis.Med Sci Monit. 2016 Mar 7;22:766-75. doi: 10.12659/msm.895558.
• [14] Epithelial alarmin levels in exhaled breath condensate in patients with idiopathic pulmonary fibrosis: A pilot study.Clin Respir J. 2019 Oct;13(10):652-656. doi: 10.1111/crj.13075. Epub 2019 Aug 19.
• [15] The signaling axis of microRNA-31/interleukin-25 regulates Th1/Th17-mediated inflammation response in colitis.Mucosal Immunol. 2017 Jul;10(4):983-995. doi: 10.1038/mi.2016.102. Epub 2016 Nov 30.
• [16] An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation.Immunity. 2018 Apr 17;48(4):787-798.e4. doi: 10.1016/j.immuni.2018.03.019. Epub 2018 Apr 10.
• [17] IL-27 regulates HIF-1-mediated VEGFA response in macrophages of diabetic retinopathy patients and healthy individuals.Cytokine. 2019 Jan;113:238-247. doi: 10.1016/j.cyto.2018.07.011. Epub 2018 Jul 13.
• [18] Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment.J Exp Clin Cancer Res. 2019 Jul 11;38(1):303. doi: 10.1186/s13046-019-1271-3.
• [19] Interleukin-25 primed mesenchymal stem cells achieve better therapeutic effects on dextran sulfate sodium-induced colitis via inhibiting Th17 immune response and inducing T regulatory cell phenotype.Am J Transl Res. 2017 Sep 15;9(9):4149-4160. eCollection 2017.
• [20] Comparative proteomic analysis between normal skin and keloid scar.Br J Dermatol. 2010 Jun;162(6):1302-15. doi: 10.1111/j.1365-2133.2010.09660.x. Epub 2010 Feb 1.
• [21] The cytokine network type I IFN-IL-27-IL-10 is augmented in murine and human lupus.J Leukoc Biol. 2019 Oct;106(4):967-975. doi: 10.1002/JLB.3AB0518-180RR. Epub 2019 Jun 19.
• [22] IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner.PLoS One. 2013 Oct 14;8(10):e76159. doi: 10.1371/journal.pone.0076159. eCollection 2013.
• [23] The IL-12 cytokine family in cardiovascular diseases.Cytokine. 2019 Oct;122:154188. doi: 10.1016/j.cyto.2017.10.010. Epub 2017 Oct 23.
• [24] Local IL-25 contributes to Th2-biased inflammatory profiles in nasal polyps.Allergy. 2018 Feb;73(2):459-469. doi: 10.1111/all.13267. Epub 2017 Sep 7.
• [25] IL-27 inhibits non-small-cell lung cancer cell metastasis by miR-935 in vitro.Onco Targets Ther. 2019 Feb 21;12:1447-1454. doi: 10.2147/OTT.S173207. eCollection 2019.
• [26] IL-25 stimulates M2 macrophage polarization and thereby promotes mitochondrial respiratory capacity and lipolysis in adipose tissues against obesity.Cell Mol Immunol. 2018 May;15(5):493-505. doi: 10.1038/cmi.2016.71. Epub 2017 Feb 13.
• [27] Murine -Herpesvirus 68 Induces Severe Lung Inflammation in IL-27-Deficient Mice with Liver Dysfunction Preventable by Oral Neomycin.J Immunol. 2018 Apr 15;200(8):2703-2713. doi: 10.4049/jimmunol.1700412. Epub 2018 Mar 2.
• [28] Association between polymorphisms of cytokine genes and secretion of IL-12p70, IL-18, and IL-27 by dendritic cells in patients with pulmonary tuberculosis.Tuberculosis (Edinb). 2019 Mar;115:56-62. doi: 10.1016/j.tube.2019.02.003. Epub 2019 Feb 6.
• [29] Mesenchymal stem cell transplantation alleviates experimental Sjgren's syndrome through IFN-/IL-27 signaling axis.Theranostics. 2019 Oct 21;9(26):8253-8265. doi: 10.7150/thno.37351. eCollection 2019.
• [30] The increased protection and pathology in Mycobacterium tuberculosis-infected IL-27R-alpha-deficient mice is supported by IL-17A and is associated with the IL-17A-induced expansion of multifunctional T cells.Mucosal Immunol. 2018 Jul;11(4):1168-1180. doi: 10.1038/s41385-018-0026-3. Epub 2018 May 4.
• [31] Functional variant in the promoter region of IL-27 alters gene transcription and confers a risk for ulcerative colitis in northern Chinese Han.Hum Immunol. 2017 Mar;78(3):287-293. doi: 10.1016/j.humimm.2017.01.002. Epub 2017 Jan 6.
• [32] Association of interleukin-27 gene polymorphisms with susceptibility to HIV infection and disease progression.J Cell Mol Med. 2019 Apr;23(4):2410-2418. doi: 10.1111/jcmm.14067. Epub 2019 Jan 10.
• [33] Anti-IgE Significantly Changes Circulating Interleukin-25, Vitamin-D and Interleukin-33 Levels in Patients with Allergic Asthma.Curr Pharm Des. 2019;25(35):3784-3795. doi: 10.2174/1381612825666190930095725.
• [34] Crystal structure and receptor-interacting residues of MYDGF - a protein mediating ischemic tissue repair.Nat Commun. 2019 Nov 26;10(1):5379. doi: 10.1038/s41467-019-13343-7.
• [35] Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages.Cytokine. 2017 Jan;89:194-200. doi: 10.1016/j.cyto.2015.12.003. Epub 2016 Feb 8.
• [36] Poly(I:C)-Mediated Death of Human Prostate Cancer Cell Lines Is Induced by Interleukin-27 Treatment.J Interferon Cytokine Res. 2019 Aug;39(8):483-494. doi: 10.1089/jir.2018.0166. Epub 2019 Apr 22.
• [37] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [38] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [39] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [40] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [41] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [42] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [43] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [44] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [45] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [46] Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
• [47] Alternatives for the worse: Molecular insights into adverse effects of bisphenol a and substitutes during human adipocyte differentiation. Environ Int. 2021 Nov;156:106730. doi: 10.1016/j.envint.2021.106730. Epub 2021 Jun 27.
• [48] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [49] Interindividual variation in gene expression responses and metabolite formation in acetaminophen-exposed primary human hepatocytes. Arch Toxicol. 2016 May;90(5):1103-15. doi: 10.1007/s00204-015-1545-2. Epub 2015 Jun 24.